Key Drivers
- Cash Cushion
- Revenue Absence
- Rising Leverage
AIAI Summary
CELC has moved from a clinical-risk story to an execution-risk story: FDA approval and guideline support validate REVTORPYK, but the stock now depends on a fast commercial ramp that can outpace heavy cash burn, rising leverage, and legal overhang from launch delays.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •Revenue Absence
- •Rising Leverage
CELC has a strong cash and liquidity cushion, but no revenue, persistent losses, negative cash burn, and rising leverage make the stock highly risky despite near-term funding flexibility.
Price Behavior
Key Price Behavior Insights:
- •Support Holding
- •Momentum Improving
- •Resistance Overhead
CELC has rebounded from late-July lows and is holding the $86–$88 support zone, but it remains below $95–$100 resistance and the broader trend over the last month is still down, so this looks like stabilization rather than a confirmed reversal.
Sharp rebound from $82.27 on 2026-07-27 after the late-July selloff
Sentiment & News
Key News Insights:
- •Delayed Launch
- •Legal Scrutiny
- •Revenue Pressure
Celcuity's FDA approval for Revtorpyk was overshadowed by a delayed late-Q3 launch, repeated securities-law investigations, and growing investor concern over near-term revenue and disclosure risk.
The news is likely to keep CELC under pressure until management clarifies launch timing, commercialization plans, and the scope of legal risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings